MA28084A1 - Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione - Google Patents

Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione

Info

Publication number
MA28084A1
MA28084A1 MA28911A MA28911A MA28084A1 MA 28084 A1 MA28084 A1 MA 28084A1 MA 28911 A MA28911 A MA 28911A MA 28911 A MA28911 A MA 28911A MA 28084 A1 MA28084 A1 MA 28084A1
Authority
MA
Morocco
Prior art keywords
polymorphic forms
isoindol
dione
piperidine
dihydro
Prior art date
Application number
MA28911A
Other languages
English (en)
Inventor
Roger Shen-Chu Chen
George W Muller
Markian S Jaworsky
Manohar T Saindane
Louise M Cameron
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MA28084A1 publication Critical patent/MA28084A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
    • B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
    • B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
    • B65D51/2857—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it
    • B65D51/2864—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by displacing or removing an element enclosing it the element being a plug or like element closing a passage between the auxiliary container and the main container
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

L¿invention concerne des formes polymorphes de 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-pipéridine-2-6-dione. L¿invention concerne aussi des compositions comportant ces formes polymorphes, des procédés pour la production desdites formes polymorphes et des procédés pour leur utilisation.
MA28911A 2003-09-04 2006-04-03 Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione MA28084A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49972303P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA28084A1 true MA28084A1 (fr) 2006-08-01

Family

ID=34272860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28911A MA28084A1 (fr) 2003-09-04 2006-04-03 Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione

Country Status (37)

Country Link
US (20) US7465800B2 (fr)
EP (7) EP3042659B8 (fr)
JP (6) JP4733037B2 (fr)
KR (3) KR101005991B1 (fr)
CN (7) CN101838261B (fr)
AP (1) AP2324A (fr)
AR (2) AR047994A1 (fr)
AT (1) ATE531369T1 (fr)
AU (2) AU2004270211B2 (fr)
BR (1) BRPI0414084A (fr)
CA (9) CA2688708C (fr)
CR (2) CR8291A (fr)
CY (1) CY1112017T1 (fr)
DK (5) DK1667682T3 (fr)
EA (1) EA009922B1 (fr)
EC (1) ECSP066467A (fr)
ES (5) ES2718927T3 (fr)
GE (1) GEP20104958B (fr)
HK (6) HK1092388A1 (fr)
HR (1) HRP20110836T1 (fr)
HU (3) HUE041265T2 (fr)
IL (5) IL174067A (fr)
IS (1) IS8340A (fr)
MA (1) MA28084A1 (fr)
ME (3) ME01572B (fr)
MX (6) MX346261B (fr)
NO (4) NO336898B1 (fr)
NZ (1) NZ546054A (fr)
OA (1) OA13250A (fr)
PE (1) PE20060284A1 (fr)
PL (5) PL3042659T3 (fr)
PT (5) PT2426118E (fr)
RS (3) RS20120339A1 (fr)
SI (2) SI1667682T1 (fr)
UA (1) UA83504C2 (fr)
WO (1) WO2005023192A2 (fr)
ZA (1) ZA200601858B (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) * 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
CN101252957A (zh) * 2005-06-30 2008-08-27 人类起源公司 使用胎盘源胶原生物纤维的鼓膜修复
SI2380887T1 (sl) 2005-06-30 2013-12-31 Celgene Corporation Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona
EP1919365A2 (fr) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Obturateur oculaire forme a partir dun tissu biologique a base de collagene derive du placenta
EP1919500A2 (fr) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Traitement d'ulceres de la jambe a l'aide d'un tissu biologique a base de collagene derive de placenta
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2007136640A2 (fr) * 2006-05-16 2007-11-29 Celgene Corporation Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
WO2008021391A1 (fr) * 2006-08-15 2008-02-21 Anthrogenesis Corporation Biomatériau à base de cordon ombilical pour usage médical
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
WO2008060377A2 (fr) 2006-10-04 2008-05-22 Anthrogenesis Corporation Compositions de tissu du cordon ombilical ou placentaire
KR20210018526A (ko) 2006-10-06 2021-02-17 안트로제네시스 코포레이션 천연(텔로펩티드) 태반 콜라겐 조성물
EP3524253A1 (fr) 2007-09-28 2019-08-14 Celularity, Inc. Suppression de tumeurs au moyen d'un perfusat placentaire humain et cellules tueuses naturelles intermediaires provenant d'un placenta humain
WO2009085234A2 (fr) 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
KR20100124710A (ko) * 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
AU2009321374A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
WO2010056384A1 (fr) * 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Solvates de lénalidomide et procédés correspondants
WO2010065939A1 (fr) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
EP2403845B1 (fr) 2009-03-02 2014-04-30 Generics [UK] Limited Procédé amélioré
WO2010129636A2 (fr) * 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lénalidomide polymorphe
EP2391355B1 (fr) 2009-05-19 2017-01-18 Celgene Corporation Préparations de 4-amino-2-(2,6-dioxopipéridine-3-yl)isoindoline-1,3-dione
CN101665484B (zh) * 2009-07-20 2012-11-21 上海皓元生物医药科技有限公司 一种制备来那度胺的方法
AU2009350978A1 (en) 2009-08-12 2012-04-05 Synthon B.V. Lenalidomide salts
EP2477973B1 (fr) * 2009-09-16 2014-08-27 Ranbaxy Laboratories Limited Procédé de préparation d'une forme cristalline du lénalidomide
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (fr) 2009-10-29 2011-05-05 Ratiopharm Gmbh Sels d'addition d'acide du lénalidomide
CN102060842B (zh) * 2009-11-02 2013-05-08 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (fr) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Procédé pour la préparation de forme b de lénalidomide
WO2011069608A1 (fr) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lénalidomide, ses formes polymorphes et mélange comprenant du s- et r-lénalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
MX337169B (es) 2010-02-11 2016-02-16 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
CA2793312C (fr) 2010-03-08 2016-06-14 Natco Pharma Limited Forme i de lenalidomide anhydre
US9193989B2 (en) 2010-06-18 2015-11-24 Taiho Pharmaceutical Co., Ltd. PRPK-TPRKB modulators and uses thereof
US9918197B2 (en) 2010-10-04 2018-03-13 Lazo Inc. Interactive advertisement environment
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
CN102070606A (zh) * 2011-02-17 2011-05-25 江苏先声药物研究有限公司 一种雷利度胺a晶型新的制备方法
CN102643266B (zh) * 2011-02-17 2015-02-18 江苏先声药物研究有限公司 一种雷利度胺b晶型的制备方法
PL2683708T3 (pl) 2011-03-11 2018-03-30 Celgene Corporation Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
WO2012127493A1 (fr) 2011-03-23 2012-09-27 Hetero Research Foundation Formes polymorphes de lénalidomide
CA2867134C (fr) 2011-03-28 2019-05-07 Sheila Dewitt Composes de 2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindoline
WO2013005229A1 (fr) * 2011-07-05 2013-01-10 Hetero Research Foundation Procédé de préparation de lénalidomide
EP2922838B1 (fr) * 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Formes solides de {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidin-3,4,4,5,5-d5)-2,6-dion}
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
WO2014152833A1 (fr) 2013-03-14 2014-09-25 Deuterx, Llc Dérivés de 3-(oxoquinazolin-3(4h)-yl-4 substitué)-3-deutéro-pipéridine-2,6-dione et des compositions les comprenant et des procédés les utilisant
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
EP2981532A4 (fr) * 2013-04-01 2016-12-14 Hetero Research Foundation Procédé de préparation de pomalidomide
SG10201705231PA (en) * 2013-09-03 2017-07-28 Fugro Chance Inc Interactive remote guidance system for seaborne vessels
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP2875817B1 (fr) * 2013-11-26 2020-03-18 Synhton B.V. Formulation pharmaceutique comprenant du lénalidomide amorphe
AU2015210999A1 (en) 2014-01-29 2016-07-21 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
WO2015113314A1 (fr) * 2014-01-30 2015-08-06 上海创诺制药有限公司 Nouvelle forme cristalline de 3- (4-amino -1,3-dihydro -1-oxo -2 h-isoindole -2-yl) -2,6-pipéridinedione et procédé de préparation correspondant
RU2016145411A (ru) * 2014-04-22 2018-05-23 Оцука Фармасьютикал Ко., Лтд. Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
CN105085473B (zh) * 2014-04-24 2019-06-18 江苏豪森药业集团有限公司 来那度胺晶型及其制备方法和医药用途
EP3137450A2 (fr) * 2014-04-26 2017-03-08 Shilpa Medicare Limited Procédé de préparation de lénalidomide cristallin
US10025472B2 (en) * 2014-06-01 2018-07-17 Apple Inc. Method and apparatus for displaying data regarding a device's traversal through a region
WO2016024286A2 (fr) 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. Procédé amélioré pour la synthèse de lénalidomide
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
US9794331B1 (en) * 2014-09-29 2017-10-17 Amazon Technologies, Inc. Block allocation based on server utilization
US10507204B2 (en) 2014-12-19 2019-12-17 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
EP3233082B1 (fr) 2014-12-19 2018-12-05 Synthon B.V. Composition pharmaceutique comprenant de la lénalidomide amorphe
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
CN104610210B (zh) * 2015-02-05 2017-06-16 天津大学 一种脱氢醋酸钠无水物制备方法
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3744318A1 (fr) 2015-08-27 2020-12-02 Grindeks, A Joint Stock Company Composition pharmaceutique pouvant incorporer la lénalidomine sous diverses variantes cristallines
MX2018007704A (es) 2015-12-22 2018-11-09 Synthon Bv Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
RU2616976C1 (ru) * 2016-04-07 2017-04-19 Олег Ростиславович Михайлов Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
WO2018013693A1 (fr) 2016-07-13 2018-01-18 Celgene Corporation Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser
TWI664172B (zh) * 2016-08-25 2019-07-01 大陸商浙江海正藥業股份有限公司 來那度胺的晶型及其製備方法和用途
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN108658935A (zh) * 2017-03-27 2018-10-16 天津大学 来那度胺新晶型、其制备方法及其医药用途
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
CN112062751A (zh) * 2017-08-04 2020-12-11 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019067792A1 (fr) 2017-09-28 2019-04-04 Celularity, Inc. Suppression de tumeur à l'aide de cellules tueuses naturelles intermédiaires dérivées du placenta humain (pink) en combinaison avec un anticorps
EP3700508A1 (fr) 2017-10-26 2020-09-02 Synbias Pharma AG Formulations à libération immédiate de lénalidomide
EP3505158A1 (fr) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Composition pharmaceutiquie comprenant des sels d'addition d'acide du lénalidomide
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
WO2019139921A1 (fr) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
CN108840908A (zh) * 2018-07-10 2018-11-20 刘凤娟 特拉匹韦的一种新晶型及其制备方法
CN111217792B (zh) * 2018-11-23 2021-09-28 欣凯医药化工中间体（上海）有限公司 一种来那度胺b晶型的制备方法
US20220218687A1 (en) 2021-01-08 2022-07-14 Starton Therapeutics, Inc. Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use
WO2023126531A1 (fr) 2021-12-31 2023-07-06 A Fine House S.A. Solution orale de lénalidomide
WO2023126530A1 (fr) 2021-12-31 2023-07-06 A Fine House S.A. Solution orale comprenant du lénalidomide

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
NZ296098A (en) * 1994-11-04 2001-05-25 Polymun Scient Immunbio Forsch Super oxide dismutase in liposome and it's use in therapy
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
DE19601303A1 (de) 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
WO1997046526A1 (fr) 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes stables d'hydrochlorure de 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-piperidine), dit hydrochlorure de donepezil et procede pour leur production
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
PT925294E (pt) * 1996-07-24 2003-04-30 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2262906C (fr) 1996-08-12 2006-10-31 Celgene Corporation Agents immunotherapiques et leur utilisation pour faire baisser les teneurs en cytokines
EP1586322B1 (fr) 1996-11-05 2008-08-20 The Children's Medical Center Corporation Compositions contenant de thalidomide et de dexamethasone pour le traitement du cancer
AU5875598A (en) 1997-02-05 1998-08-26 University Of Hertfordshire Preparation of spheroids and their use in medicin or diagnosis
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
TR200101501T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı.
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
TR200102688T2 (tr) 1999-03-18 2002-01-21 Celgene Corporation İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
CA2319872C (fr) 2000-02-02 2012-06-19 Chun-Ying Huang Composition pharmaceutique pour le traitement du carcinome hepatocellulaire
CN1429121A (zh) 2000-03-17 2003-07-09 细胞治疗公司 聚谷氨酸－喜树碱结合物及其制备方法
EP1272189A4 (fr) 2000-03-31 2004-01-14 Celgene Corp Inhibition de l'activite de l'enzyme cyclooxygenase-2
ES2258084T3 (es) 2000-05-15 2006-08-16 Celgene Corporation Composiciones para el tratamiento de cancer que comprenden un inhibidor de topoisomerasa y talidomida.
JP2004509961A (ja) * 2000-09-26 2004-04-02 ドクター・レディーズ・リサーチ・ファウンデーション ５−［４−［２−［ｎ−メチル−ｎ−（２−ピリジル）アミノ］エトキシ］ベンジル］チアゾリジン−２，４−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
DK1423115T3 (da) 2001-08-06 2009-06-15 Childrens Medical Center Nitrogen-substituerede thalidomidanalogers antiangiogenetiske aktivitet
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
WO2003086373A1 (fr) 2002-04-12 2003-10-23 Celgene Corporation Techniques d'identification de modulateurs d'angiogenese, composes decouverts par ces techniques et techniques de traitement utilisant ces composes
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2476983C (fr) 2002-05-17 2011-01-25 Celgene Corporation Methodes et compositions a base de 3-(4-amino-1-oxo-1,3- dihydroisoindol-2-yl)-piperidine-2,6-dione pour le traitement et la gestion de myelome multiple
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7511032B2 (en) 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
JP2008512379A (ja) 2004-09-03 2008-04-24 セルジーン・コーポレーション 置換２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン類の調製方法
WO2007136640A2 (fr) 2006-05-16 2007-11-29 Celgene Corporation Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
US20090092343A1 (en) * 2007-10-05 2009-04-09 Mary Thomson Locking Bag with Locking Handle
KR20100124710A (ko) 2008-03-11 2010-11-29 닥터 레디스 레보러터리즈 리미티드 레날리도미드의 제조
WO2009111948A1 (fr) 2008-03-13 2009-09-17 天津和美生物技术有限公司 Sels de 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)pipéridine-2,6-dione ou ses dérivés, leurs polymorphes, procédés de préparation et utilisations associés
US8071638B2 (en) 2008-08-14 2011-12-06 Teva Pharmaceutical Industries Ltd. Solid states of atorvastatin potassium
AU2009321374A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
WO2010056384A1 (fr) 2008-11-17 2010-05-20 Dr. Reddy's Laboratories Ltd. Solvates de lénalidomide et procédés correspondants
EP2403845B1 (fr) 2009-03-02 2014-04-30 Generics [UK] Limited Procédé amélioré
WO2010129636A2 (fr) 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lénalidomide polymorphe
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
AU2009350978A1 (en) 2009-08-12 2012-04-05 Synthon B.V. Lenalidomide salts
US20120184746A1 (en) 2009-09-03 2012-07-19 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
EP2477973B1 (fr) 2009-09-16 2014-08-27 Ranbaxy Laboratories Limited Procédé de préparation d'une forme cristalline du lénalidomide
TWI475014B (zh) 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011050962A1 (fr) 2009-10-29 2011-05-05 Ratiopharm Gmbh Sels d'addition d'acide du lénalidomide
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011061611A1 (fr) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Procédé pour la préparation de forme b de lénalidomide
WO2011064574A1 (fr) 2009-11-24 2011-06-03 Generics [Uk] Limited Procédés de hplc permettant la détection de la lénalidomide
WO2011069608A1 (fr) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lénalidomide, ses formes polymorphes et mélange comprenant du s- et r-lénalidomide
CN101817813B (zh) 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
CA2793312C (fr) 2010-03-08 2016-06-14 Natco Pharma Limited Forme i de lenalidomide anhydre
CN101791288B (zh) 2010-04-07 2011-12-28 南京卡文迪许生物工程技术有限公司 一种稳定的来那度胺口服固体制剂
CN102453021A (zh) * 2010-10-22 2012-05-16 重庆医药工业研究院有限责任公司 来那度胺的新晶型及其制备方法

Also Published As

Publication number Publication date
MX342071B (es) 2016-09-13
WO2005023192A3 (fr) 2005-09-29
AU2004270211B2 (en) 2008-10-23
RS53104B (en) 2014-06-30
HK1202531A1 (en) 2015-10-02
IL174067A (en) 2015-07-30
JP2011137024A (ja) 2011-07-14
ES2718927T3 (es) 2019-07-05
ME01571B (fr) 2014-09-20
RS20060158A (en) 2008-08-07
EP2425836A1 (fr) 2012-03-07
SI1667682T1 (sl) 2011-12-30
PL3042659T3 (pl) 2019-04-30
CN102675281B (zh) 2016-01-20
HUE041265T2 (hu) 2019-05-28
US7465800B2 (en) 2008-12-16
CN1871003A (zh) 2006-11-29
EP2426118B1 (fr) 2013-01-23
EP3045176A1 (fr) 2016-07-20
US20170121305A1 (en) 2017-05-04
US8431598B2 (en) 2013-04-30
HK1167646A1 (fr) 2012-12-07
HK1148274A1 (fr) 2011-09-02
ME01530B (me) 2011-10-10
CN1871003B (zh) 2012-03-14
MXPA06001994A (es) 2006-05-31
CA2688694C (fr) 2011-08-09
DK1667682T3 (da) 2011-12-12
CN101838261B (zh) 2013-07-10
DK2426118T3 (da) 2013-03-25
CA2687927A1 (fr) 2005-03-17
PT3042659T (pt) 2019-02-04
HK1148974A1 (fr) 2011-09-23
US8193219B2 (en) 2012-06-05
AU2009200257A1 (en) 2009-02-19
WO2005023192A2 (fr) 2005-03-17
JP2007504248A (ja) 2007-03-01
IS8340A (is) 2006-03-07
AU2004270211A1 (en) 2005-03-17
EA009922B1 (ru) 2008-04-28
PT2426118E (pt) 2013-04-04
EP3045176B8 (fr) 2018-12-12
US20110288127A1 (en) 2011-11-24
ES2376879T3 (es) 2012-03-20
US20190218201A1 (en) 2019-07-18
ZA200601858B (en) 2007-07-25
US20090062343A1 (en) 2009-03-05
CA2687924C (fr) 2011-08-09
PL2426118T3 (pl) 2013-08-30
CN102675281A (zh) 2012-09-19
NO341039B1 (no) 2017-08-14
EP2426118A1 (fr) 2012-03-07
PT1667682E (pt) 2012-01-19
JP2013209407A (ja) 2013-10-10
IL207458A (en) 2015-08-31
AP2324A (en) 2011-11-21
IL174067A0 (en) 2006-08-01
CN104059052A (zh) 2014-09-24
EP3042659A1 (fr) 2016-07-13
US20220127244A1 (en) 2022-04-28
ME01572B (me) 2014-09-20
US20120029020A1 (en) 2012-02-02
US20170121303A1 (en) 2017-05-04
HUE042071T2 (hu) 2019-06-28
NO20061528L (no) 2006-06-02
OA13250A (en) 2007-01-31
MX342025B (es) 2016-09-12
EA200600535A1 (ru) 2006-08-25
CA2741575A1 (fr) 2005-03-17
CA2741575C (fr) 2013-07-16
US20120022106A1 (en) 2012-01-26
KR101005991B1 (ko) 2011-01-05
CA2688709A1 (fr) 2005-03-17
CR8291A (es) 2007-09-17
CN102060843B (zh) 2013-08-14
US10590104B2 (en) 2020-03-17
CA2537092A1 (fr) 2005-03-17
CA2741412C (fr) 2013-07-16
KR20080063862A (ko) 2008-07-07
CA2741412A1 (fr) 2005-03-17
HUE041282T2 (hu) 2019-05-28
CN101838261A (zh) 2010-09-22
ATE531369T1 (de) 2011-11-15
KR20090086647A (ko) 2009-08-13
AU2009200257B2 (en) 2012-02-02
CN102060843A (zh) 2011-05-18
US20180072700A1 (en) 2018-03-15
CA2687927C (fr) 2012-05-29
US8143286B2 (en) 2012-03-27
KR100979869B1 (ko) 2010-09-02
EP1667682A4 (fr) 2009-05-06
CA2688709C (fr) 2011-08-09
JP5925418B2 (ja) 2016-05-25
CA2537092C (fr) 2011-08-09
US9371309B2 (en) 2016-06-21
PT3045176T (pt) 2019-02-04
US9365538B2 (en) 2016-06-14
CA2688694A1 (fr) 2005-03-17
EP3042659B1 (fr) 2018-11-07
JP4733037B2 (ja) 2011-07-27
MX346260B (es) 2017-03-13
PL3045175T3 (pl) 2019-04-30
CA2688708A1 (fr) 2005-03-17
HRP20110836T1 (hr) 2011-12-31
JP2011006470A (ja) 2011-01-13
RS20120339A1 (en) 2013-04-30
CR10967A (es) 2009-12-10
DK3042659T3 (en) 2019-02-25
DK3045175T3 (en) 2019-03-04
CN102584788A (zh) 2012-07-18
JP5309104B2 (ja) 2013-10-09
ES2402808T3 (es) 2013-05-09
US20090187023A1 (en) 2009-07-23
CA2688695A1 (fr) 2005-03-17
US20170121304A1 (en) 2017-05-04
JP2014094957A (ja) 2014-05-22
EP3045175B8 (fr) 2018-12-19
NO341035B1 (no) 2017-08-07
EP1667682B1 (fr) 2011-11-02
US20110015228A1 (en) 2011-01-20
NO336898B1 (no) 2015-11-23
US20050096351A1 (en) 2005-05-05
US11136306B2 (en) 2021-10-05
RS20120340A1 (en) 2013-04-30
US7977357B2 (en) 2011-07-12
PL3045176T3 (pl) 2019-04-30
KR20060087543A (ko) 2006-08-02
EP3045175A1 (fr) 2016-07-20
JP6200977B2 (ja) 2017-09-20
HK1092388A1 (fr) 2007-02-09
CY1112017T1 (el) 2015-11-04
NO20160131A1 (no) 2016-01-28
MX346261B (es) 2017-03-13
NZ546054A (en) 2009-12-24
ECSP066467A (es) 2006-09-18
ES2718926T3 (es) 2019-07-05
PT3045175T (pt) 2019-02-04
IL225792A0 (en) 2013-06-27
NO20161012A1 (no) 2016-06-15
EP3045175B1 (fr) 2018-11-07
US20090149499A1 (en) 2009-06-11
US20090149500A1 (en) 2009-06-11
EP3045176B1 (fr) 2018-11-07
AR047994A1 (es) 2006-03-15
US20200239431A1 (en) 2020-07-30
GEP20104958B (en) 2010-04-26
SI2426118T1 (sl) 2013-06-28
US7855217B2 (en) 2010-12-21
CA2688695C (fr) 2011-08-09
NO337446B1 (no) 2016-04-11
US11655232B2 (en) 2023-05-23
US8058443B2 (en) 2011-11-15
IL238911A0 (en) 2015-06-30
IL207458A0 (en) 2010-12-30
PL1667682T3 (pl) 2012-04-30
EP3042659B8 (fr) 2018-12-19
CA2688708C (fr) 2011-08-09
US8822499B2 (en) 2014-09-02
AR102756A2 (es) 2017-03-22
US20090176832A1 (en) 2009-07-09
AP2006003558A0 (en) 2006-04-30
CN101863878A (zh) 2010-10-20
JP2016074734A (ja) 2016-05-12
US9353080B2 (en) 2016-05-31
PE20060284A1 (es) 2006-04-13
IL225791A0 (en) 2013-06-27
MX346372B (es) 2017-03-16
BRPI0414084A (pt) 2006-10-24
US20160009684A1 (en) 2016-01-14
US20120029019A1 (en) 2012-02-02
US20120046316A1 (en) 2012-02-23
HK1157772A1 (fr) 2012-07-06
EP1667682A2 (fr) 2006-06-14
UA83504C2 (en) 2008-07-25
NO20150253L (no) 2006-06-02
CA2687924A1 (fr) 2005-03-17
CN101863878B (zh) 2012-07-18
DK3045176T3 (en) 2019-02-25
ES2718925T3 (es) 2019-07-05
EP3459544A1 (fr) 2019-03-27

Similar Documents

Publication Publication Date Title
MA28084A1 (fr) Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione
IL190437A0 (en) Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
WO2007074130A3 (fr) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepine-2(1h)-one
CY1113926T1 (el) Μεθοδος κατασκευης πολυμορφικων μορφων 3-(4-αμινο-1-οξο-1,3-διϋδρο-ισοϊνδολ-2-υλ)-πιπεριδινο-2,6-διονης
AU2013203194B9 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione